AFP and hepatocellular carcinoma: Following this, another VEGFR2 monoclonal antibody, ramucirumab, has been approved by the FDA for advanced HCC patients who previously recieved sorafenib and had an AFP ≥ 400 ng/mL.34 The success of these agents demonstrates the substantial role of VEGFR in HCC treatment.